Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C

doi:10.4254/wjh.v6.i7.520

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 7

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5294)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

316

WORD

333

HTML

2187

Figures (1-2)

139

Tables (1-5)

129

Sum=3104

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1111

Download

1079

Sum=2190

Jul 27, 2014 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Hepatol. Jul 27, 2014; 6(7): 520-526
Published online Jul 27, 2014. doi: 10.4254/wjh.v6.i7.520

Table 3 Percentage of patients who responded in terms of rapid virologic response, early virologic response, end of treatment virologic response, and sustained virologic response in genotypes 1, 3 and 4 by per protocol analysis

Parameter	Genotype 1	Genotype 3¹	Genotype 4
	(n/N)	(n/N)	(n/N)
RVR	25.9% (7/27)	74.1% (40/54)	58.8% (10/17)
EVR	74.1% (20/27)	100% (49/49)	88.2% (15/17)
ETVR	84.2% (16/19)	89.8% (44/49)	75.0% (12/16)
SVR	60.0% (12/20)	76.6% (36/47)	60.0% (9/15)

¹Includes one patient with genotype 2; n: Number of responding patients; N: Total number of patients studied; RVR: Rapid virologic response; EVR: Early virologic response; SVR: Sustained virologic response; ETVR: End of treatment virologic response.

Citation: Rao P, Koshy A, Philip J, Premaletha N, Varghese J, Narayanasamy K, Mohindra S, Pai NV, Agarwal MK, Konar A, Vora HB. Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C. World J Hepatol 2014; 6(7): 520-526
URL: https://www.wjgnet.com/1948-5182/full/v6/i7/520.htm
DOI: https://dx.doi.org/10.4254/wjh.v6.i7.520